nDatalyze (CNSX:NDAT) - Stock Price, News & Analysis

NDAT Stock Overview

Provides technology-based health-related solutions in Canada, the United States, and internationally. More details

NDAT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the Canadian market

Earnings have declined by 22.4% per year over past 5 years

Does not have a meaningful market cap (CA$4M)

Makes less than USD$1m in revenue (CA$47K)

+ 1 more risk

nDatalyze Corp. Competitors

Telecure Technologies

CNSX:TELE

CA$7.6m

Reliq Health Technologies

TSXV:RHT

CA$47.3m

Highmark Interactive

TSXV:HMRK

CA$617.1k

Avricore Health

TSXV:AVCR

CA$6.1m

Price History & Performance

Summary of all time highs, changes and price drops for nDatalyze
Historical stock prices
Current Share Price	CA$0.09
52 Week High	CA$0.17
52 Week Low	CA$0.085
Beta	1.04
11 Month Change	-18.18%
3 Month Change	-30.77%
1 Year Change	-43.75%
33 Year Change	-53.85%
5 Year Change	12.50%
Change since IPO	28.57%

Recent updates

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Jan 14

Shareholder Returns

	NDAT	CA Healthcare Services	CA Market
7D	-14.3%	0.2%	0.7%
1Y	-43.8%	97.0%	21.7%

Return vs Industry: NDAT underperformed the Canadian Healthcare Services industry which returned 97% over the past year.

Return vs Market: NDAT underperformed the Canadian Market which returned 21.7% over the past year.

Price Volatility

Is NDAT's price volatile compared to industry and market?
NDAT volatility
NDAT Average Weekly Movement	20.5%
Healthcare Services Industry Average Movement	8.1%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: NDAT's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: NDAT's weekly volatility has increased from 14% to 20% over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	James Durward	www.ndatalyze.com

nDatalyze Corp. provides technology-based health-related solutions in Canada, the United States, and internationally. It offers YMI, a machine-learning-based online mental health application that addresses misdiagnosis and mispresciption, as well as provides resources to connect with experts for treatment. The company was formerly known as MedXtractor Corp. and changed its name to nDatalyze Corp. in October 2021.

nDatalyze Corp. Fundamentals Summary

How do nDatalyze's earnings and revenue compare to its market cap?
NDAT fundamental statistics
Market cap	CA$3.82m
Earnings (TTM)	-CA$668.00k
Revenue (TTM)	CA$47.23k

80.8x

P/S Ratio

-5.7x

P/E Ratio

Is NDAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NDAT income statement (TTM)
Revenue	CA$47.23k
Cost of Revenue	CA$2.87k
Gross Profit	CA$44.36k
Other Expenses	CA$712.36k
Earnings	-CA$668.00k

Last Reported Earnings

Aug 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.016
Gross Margin	93.92%
Net Profit Margin	-1,414.27%
Debt/Equity Ratio	0%

How did NDAT perform over the long term?

See historical performance and comparison

NDAT Stock Overview

Risk Analysis

nDatalyze Corp. Competitors

CNSX:TELE

CA$7.6m

TSXV:RHT

CA$47.3m

TSXV:HMRK

CA$617.1k

TSXV:AVCR

CA$6.1m

Price History & Performance

Recent News & Updates

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

Recent updates

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

Shareholder Returns

Price Volatility

About the Company

nDatalyze Corp. Fundamentals Summary

80.8x

-5.7x

Earnings & Revenue